TCR-T

What is TCR-T?

TCR-T (TCR-T cell therapy) is a cell therapy modality that introduces $\alpha\beta$ TCR genes that recognize specific antigen peptide-HLA complexes (pHLA) into the patient's own or allogeneic T cells. While CAR-T primarily targets cell surface antigens,TCR-T also recognizes antigenic peptides derived from intracellular proteins (such as NY-ESO-1, MAGE-A4, and KRAS mutants).Yes, we can. Therefore, it has a wide range of target antigen options and is expected to be a promising next-generation modality for solid tumors.

Representative examples of TCR-T cell therapy

Afami-cel (Afamitresgene autoleucel)

Afami-cel is an HLA-A*02-restricted TCR-T targeting MAGE-A4 and is a representative example that has gained FDA approval for solid tumors such as synovial sarcoma.Affinity-enhanced design with artificially increased affinity of wild-type TCRis a feature, and while high antitumor efficacy is expected, the evaluation of cross-reactivity risk associated with higher affinity has become a key focus in development.

Tebentafusp

Tebentafusp is not strictly a TCR-T, but rather an ImmTAC-type bispecific molecule that fuses a soluble TCR and an anti-CD3 antibody.approved drug restricted by HLA-A*02 targeting gp100It is a prime example of a distinct biopharmaceutical modality that leverages the recognition capabilities of the TCR by combining the recognition of intracellular antigens by soluble TCRs with T-cell recruitment.

Neoantigen-Targeted Personalized TCR-T Therapy

Neoantigen-targeted personalized TCR-T cells are individualized TCR-T cells that target mutant peptides (such as KRAS G12D and TP53 mutations) identified through cancer genome analysis specific to each patient.Constrained by patient-specific HLA alleles (HLA-A, B, C, etc.)Therefore, unlike TCR-T targeting common antigens, rapid antigen and HLA evaluation and development tailored to each patient are required.

Key challenges in TCR-T cell development

"Off-target (recognition of similar peptides)/off-tumor cross-reactivity" Associated with Enhanced TCR Affinity and TCR Mismatching

Modifying the CDR3 region of a TCR to increase its affinity for a tumor antigen increases the risk of off-target/off-tumor toxicity, in which the TCR mistakenly recognizes similar peptides in normal tissue. A prime example of this is,A Case in Which the MAGE-A3 Target TCR Cross-Reacted with a Cardiac Titin Peptide, Leading to Severe CardiotoxicityThere are some issues. Additionally, there is a risk that the α/β chains of the introduced TCR will mismatch with the endogenous chains, leading to unpredictable autoantigen attacks.

Tumor-Induced “HLA Downregulation and Antigen Loss” and T Cell Dysfunction in the Tumor Microenvironment (TME)

The antitumor efficacy of TCR-T therapy depends on the expression of MHC Class I (HLA) on tumor cells. Therefore, immune evasion due to B2M mutations or HLA deficiency, as well as antigen shedding, can lead to treatment resistance.In the immunosuppressive TME, which includes PD-L1, TGF-β, MDSCs, and others, TCR-T cells are prone to functional exhaustion.This is also an important issue.

Interpatient Variability Due to HLA Allele Polymorphisms and the Limitations of Animal Models Due to “Species Differences”

Because TCRs recognize specific HLA (e.g., HLA-A*02:01) and peptide complexes, patient-specific reactivity varies depending on HLA allele polymorphisms.In standard immunodeficient mice and the like, it is not possible to fully replicate the reactivity of human TCR-T cells or their effects on normal tissues,...Nonclinical evaluations that accurately predict safety and efficacy in humans remain a major challenge.

Nonclinical Evaluations Required for TCR-T Development

Evaluation 1: “In Silico & In Vitro Similar Peptide and Xeno-reactivity Analysis” to Comprehensively Rule Out Critical Cross-Reactivity

In TCR-T therapy, it is important to evaluate unexpected off-target toxicity caused by TCRs with enhanced affinity. We conduct an in silico search of the entire human proteome for sequences similar to the target peptide, andComprehensive evaluation of cross-reactivity risk by combining HLA immunopeptidomics via LC-MS/MS with in vitro assessment using human primary cellsI will do so.

Evaluation 2: “Evaluation of 3D Human Normal Tissue Organoids and iPS-Derived Organ Models” to Visualize On-Target and Off-Tumor Toxicity

In TCR-T therapy, it is important to evaluate “on-target, off-tumor” toxicity, in which the target peptide is also presented on normal organs.Evaluation of tissue toxicity using iPS-derived cardiomyocytes and neural cells, as well as human normal tissue organoidsWe also identify the “Affinity Window,” which allows us to balance TCR affinity and safety. Real-time cytotoxicity analysis (RTCA) is also useful.

Evaluation 3: “Human HLA Transgenic Mouse Disease Model” for Evaluating HLA Binding Affinity and Pharmacokinetics

Since ordinary mice cannot replicate the HLA recognition of human TCR-T cells, specialized models, such as human HLA transgenic mice, are required.Evaluation of Tumor Accumulation, Persistence, and Antitumor Efficacy in HLA-Expressing PDX ModelsWe will analyze cellular kinetics by tracking TCR copy numbers using ddPCR.

Evaluation 4: “Integrated Analysis of Single-Cell RNA-seq and TCR-seq” to Elucidate TCR Mismatching and Tumor Resistance

In TCR-T therapy, it is important to analyze, at the cellular level, mismatches between the introduced TCR and endogenous TCRs, T cell dysfunction in the TME, and tumor-mediated HLA loss.Integrating scRNA-seq and scTCR-seqIt simultaneously analyzes TCR α/β chain expression, cytotoxic/exhausted states, and HLA/B2M expression.

Key points when choosing a contract research organization (CRO) for non-clinical studies

Due to their ability to target intracellular antigens, TCR-T cells are expected to become a leading treatment modality for solid tumors. However, there are also many challenges, such as cross-reactivity, HLA polymorphisms, and dysfunction caused by the tumor microenvironment (TME); therefore, comprehensive preclinical evaluation and the strategic selection of a CRO to support it are key to successful development.Moving forward, high-precision safety evaluations and advances in personalized technologies will be critical.